CIK 0001453687
- Non-accelerated filer
- Smaller reporting company
Cartesian Therapeutics, Inc.
Sign in to watch- Ticker
- RNAC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 301-348-8698
- Business address
- 7495 NEW HORIZON WAY, FREDERICK, MD, 21703
- Former names
- SELECTA BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-02 | DeSilva Nishan M Director | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2023-01-02 | Johnston Lloyd P. Chief Operations Officer | Grant or award | +100,000 | 275,299 | ||
| 2023-01-02 | Johnston Lloyd P. Chief Operations Officer | Grant or award · Employee Stock Option (right to buy) | +475,000 | 475,000 | ||
| 2023-01-02 | Kishimoto Takashi Kei Chief Scientific Officer | Grant or award | +100,000 | 374,100 | ||
| 2023-01-02 | Kishimoto Takashi Kei Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +475,000 | 475,000 | ||
| 2023-01-02 | Sallin Aymeric Director | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2023-01-02 | SPRINGER TIMOTHY A Director | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2023-01-02 | TRABER PETER G Chief Medical Officer | Grant or award | +200,000 | 457,765 | ||
| 2023-01-02 | TRABER PETER G Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +900,000 | 900,000 | ||
| 2023-01-02 | ZENNER PATRICK J Director | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2022-12-05 | Brunn Carsten President and CEO | Sale | −4,522 | $1.33 | $6K | 544,283 |
| 2022-12-01 | Brunn Carsten President and CEO | Option exercise | +10,938 | 548,805 | ||
| 2022-12-01 | Brunn Carsten President and CEO | Option exercise · Restricted Stock Units | −10,938 | 0 | ||
| 2022-11-28 | Davis Blaine Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +1,250,000 | 1,250,000 | ||
| 2022-09-28 | Brunn Carsten President and CEO | Sale | −2,692 | $1.66 | $4K | 537,867 |
| 2022-09-02 | Brunn Carsten President and CEO | Sale | −4,768 | $1.85 | $9K | 540,559 |
| 2022-09-01 | Brunn Carsten President and CEO | Option exercise | +10,937 | 545,327 | ||
| 2022-09-01 | Brunn Carsten President and CEO | Option exercise · Restricted Stock Units | −10,937 | 10,938 | ||
| 2022-06-13 | COX CARRIE SMITH Director | Purchase | +130,000 | $1.15 | $150K | 212,881 |
| 2022-06-01 | Brunn Carsten President and CEO | Option exercise | +10,938 | 534,390 |
Page 20 of 25 · 495 trades